Nonimmunosuppressive cyclosporin analog that reverses multidrug resistance (MDR) by inhibiting cellular drug efflux mediated by P-glycoprotein, q.v. Prepn: P. Bollinger et al., EP 296122; eidem, US 5525590 (1988, 1996 both to Sandoz). Pharmacology: D. Boesch et al., Exp. Cell Res. 196, 26 (1991). Clinical pharmacokinetics: R. M. Lush et al., J. Clin. Pharmacol. 37, 123 (1997). HPLC determn in blood: M. G. Scott et al., Clin. Chem. 43, 505 (1997). Clinical evaluation in multiple myeloma: P. Sonneveld et al., Leukemia 10, 1741 (1996); in acute myelogenous leukemia: R. Advani et al., Blood 93, 787 (1999). Review of pharmacology and clinical efficacy: F. Loor, Expert Opin. Invest. Drugs 8, 807-835 (1999).
Antineoplastic adjunct (chemosensitizer).
Antineoplastic Adjunct; Chemosensitizer